C-C motif chemokine receptors (CCR1, CCR3, CCR5) (CCR1, CCR3, CCR5)

C-C motif chemokine receptors, primarily CCR1, CCR3, and CCR5, are G protein-coupled receptors (GPCRs) that serve as the principal signaling targets for the chemokine CCL5, also known as RANTES. These receptors are widely expressed on various immune cells, including T lymphocytes, macrophages, and eosinophils, where they orchestrate chemotaxis and activation in response to inflammatory stimuli [1, 2, 6]. Beyond their role in immune cell trafficking, these receptors are involved in diverse pathological processes, including chronic inflammation, cardiovascular diseases, and neurodegeneration [5, 10, 12]. CCR5 is particularly significant as a major co-receptor for HIV-1 entry into host cells [1, 5]. In cancer, the CCL5-receptor axis is frequently hijacked to promote tumor growth, metastasis, and the recruitment of immunosuppressive cells to the tumor microenvironment [4, 14]. Therapeutic interventions targeting these receptors include small-molecule antagonists and monoclonal antibodies, with Maraviroc being the first FDA-approved CCR5 antagonist for HIV treatment [16, 20]. Current clinical research is exploring the efficacy of dual or multi-receptor blockade in treating various solid tumors and inflammatory conditions [14, 16].

Other names

RANTES receptorsC-C chemokine receptorsCD191 (CCR1)CD193 (CCR3)CD195 (CCR5)

Antagonism of C-C motif chemokine receptors to competitively or allosterically inhibit the binding of CCL5 and other cognate ligands, thereby blocking downstream signaling pathways (e.g., PI3K/Akt, MAPK) and preventing leukocyte chemotaxis or viral entry.